AU2007220094B2 - Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors - Google Patents

Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors Download PDF

Info

Publication number
AU2007220094B2
AU2007220094B2 AU2007220094A AU2007220094A AU2007220094B2 AU 2007220094 B2 AU2007220094 B2 AU 2007220094B2 AU 2007220094 A AU2007220094 A AU 2007220094A AU 2007220094 A AU2007220094 A AU 2007220094A AU 2007220094 B2 AU2007220094 B2 AU 2007220094B2
Authority
AU
Australia
Prior art keywords
fatty acid
cells
acid oxidation
drug
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007220094A
Other languages
English (en)
Other versions
AU2007220094A1 (en
Inventor
Sarah S. Bacus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targeted Molecular Diagnostics LLC
Original Assignee
Targeted Molecular Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Molecular Diagnostics LLC filed Critical Targeted Molecular Diagnostics LLC
Publication of AU2007220094A1 publication Critical patent/AU2007220094A1/en
Application granted granted Critical
Publication of AU2007220094B2 publication Critical patent/AU2007220094B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
AU2007220094A 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors Ceased AU2007220094B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US77709606P 2006-02-27 2006-02-27
US60/777,096 2006-02-27
US82123006P 2006-08-02 2006-08-02
US60/821,230 2006-08-02
US82737206P 2006-09-28 2006-09-28
US60/827,372 2006-09-28
US82834506P 2006-10-05 2006-10-05
US60/828,345 2006-10-05
US86773606P 2006-11-29 2006-11-29
US60/867,736 2006-11-29
PCT/US2007/062871 WO2007101191A2 (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2007220094A1 AU2007220094A1 (en) 2007-09-07
AU2007220094B2 true AU2007220094B2 (en) 2013-12-05

Family

ID=38459790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007220094A Ceased AU2007220094B2 (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Country Status (11)

Country Link
US (2) US8709738B2 (enExample)
EP (1) EP1996939B1 (enExample)
JP (2) JP5539653B2 (enExample)
KR (1) KR101390625B1 (enExample)
CN (2) CN101438155B (enExample)
AU (1) AU2007220094B2 (enExample)
CA (1) CA2643846A1 (enExample)
ES (1) ES2475162T3 (enExample)
IL (1) IL193715A (enExample)
NZ (2) NZ571465A (enExample)
WO (1) WO2007101191A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
EP3739041A1 (en) 2014-03-27 2020-11-18 The Salk Institute for Biological Studies Compositions and methods for treating type 1 and type 2 diabetes and related disorders
WO2016138464A1 (en) * 2015-02-27 2016-09-01 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
CA3025344A1 (en) 2016-05-25 2017-11-30 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
US11369608B2 (en) 2017-10-27 2022-06-28 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting AVIL expression
TWI711458B (zh) * 2019-07-08 2020-12-01 大江生醫股份有限公司 植物發酵物及其製備方法與用於胃臟保健的用途
KR102493664B1 (ko) 2020-01-29 2023-02-01 한국화학연구원 심장 독성 예측 모델링 시스템 및 모델링 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042360A2 (en) * 2002-11-04 2004-05-21 The Regents Of The Univeristy Of California Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
US20050089899A1 (en) * 2003-08-28 2005-04-28 Daniel Birnbaum Identification of an ERBB2 gene expression signature in breast cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
EP1438420B1 (en) * 2001-09-24 2009-09-16 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042360A2 (en) * 2002-11-04 2004-05-21 The Regents Of The Univeristy Of California Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
US20050089899A1 (en) * 2003-08-28 2005-04-28 Daniel Birnbaum Identification of an ERBB2 gene expression signature in breast cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An et al (2005) American Journal of Physiology, January, 288:E246-E253 *
Huss et al (2005) Journal of Clinical Investigation, March, 115(3):547-555 *
Schneider et al (2002) Seminars in Oncology, June, 29(3 suppl 11):22-28 *
Tokarska-Schlattner et al (2005) American Journal of Physiology, July, 289:H37-H47 *

Also Published As

Publication number Publication date
JP5539653B2 (ja) 2014-07-02
NZ571465A (en) 2011-09-30
WO2007101191A2 (en) 2007-09-07
JP2013063090A (ja) 2013-04-11
KR101390625B1 (ko) 2014-04-29
IL193715A (en) 2014-06-30
CN101438155A (zh) 2009-05-20
WO2007101191A3 (en) 2007-12-13
CA2643846A1 (en) 2007-09-07
ES2475162T3 (es) 2014-07-10
KR20090008194A (ko) 2009-01-21
EP1996939A2 (en) 2008-12-03
AU2007220094A1 (en) 2007-09-07
NZ594178A (en) 2013-02-22
EP1996939B1 (en) 2014-03-26
JP2009533017A (ja) 2009-09-17
CN101438155B (zh) 2013-04-24
US20090186910A1 (en) 2009-07-23
US8709738B2 (en) 2014-04-29
CN103217520A (zh) 2013-07-24
EP1996939A4 (en) 2009-07-15
US20130288285A1 (en) 2013-10-31
IL193715A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
US20130288285A1 (en) Methods for predicting cardiac toxicity
WO2008016730A2 (en) Compositions and methods for reducing cellular fat
Zhenyukh et al. High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation
Shimokawa et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation
Aliaga et al. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells
Boatright et al. Regulation of endogenous dopamine release in amphibian retina by melatonin: the role of GABA
Herbert et al. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells
Long et al. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes
Guo et al. OX2R activation induces PKC-mediated ERK and CREB phosphorylation
Kitamura et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells
Teshigawara et al. Role of Krüppel-like factor 15 in PEPCK gene expression in the liver
Canga et al. 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin increases cardiac myocyte intracellular calcium and progressively impairs ventricular contractile responses to isoproterenol and to calcium in chick embryo hearts.
Ahluwalia et al. Impaired angiogenesis in aging myocardial microvascular endothelial cells is associated with reduced importin alpha and decreased nuclear transport of HIF1 alpha: mechanistic implications.
Baquero et al. Insulin activates epithelial sodium channel (ENaC) via phosphoinositide 3-kinase in mammalian taste receptor cells
Kihara et al. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells
Razzoli et al. A key role for P2RX5 in brown adipocyte differentiation and energy homeostasis
Singh et al. Proteomic identification of 14-3-3ζ as an adapter for IGF-1 and Akt/GSK-3β signaling and survival of renal mesangial cells
Yan et al. Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53
Sidorenko et al. Ryanodine receptor stabilizer S-107 rescues slow-type rat soleus muscle function after 7-day hindlimb unloading
Balogh et al. Urocortin stimulates ERK1/2 phosphorylation and proliferation but reduces ATP production of MCF7 breast cancer cells
Li et al. High-fat feeding in cardiomyocyte-restricted PPARδ knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes
US7915255B2 (en) Metabolism-modulating agents and uses therefor
Di Cerbo et al. Immunoglobulins from Graves' patients stimulate phospholipase-A2 in FRTL5 thyroid cells
RU2345785C2 (ru) Применение рам
JPH11509095A (ja) 薬物の化学療法の有効性を評価するためのアッセイ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired